PRECISION BIOSCIENCES INC

NASDAQ: DTIL (Precision BioSciences, Inc.)

Last update: yesterday, 11:18AM

0.863

0.08 (10.07%)

Previous Close 0.784
Open 0.794
Volume 991,940
Avg. Volume (3M) 560,777
Market Cap 98,146,464
Price / Sales 0.550
Price / Book 1.03
52 Weeks Range
0.682 (-20%) — 2.21 (156%)
Earnings Date 7 Aug 2023 - 11 Aug 2023
Profit Margin 10.43%
Operating Margin (TTM) -3,894.36%
Diluted EPS (TTM) 1.04
Quarterly Revenue Growth (YOY) -95.60%
Total Debt/Equity (MRQ) 53.28%
Current Ratio (MRQ) 6.34
Operating Cash Flow (TTM) -58.45 M
Levered Free Cash Flow (TTM) -2.34 M
Return on Assets (TTM) -11.04%
Return on Equity (TTM) 19.05%

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Bearish
Biotechnology (Global) Mixed Bearish
Stock Precision BioSciences, Inc. Bearish Bearish

AIStockmoo Score

1.1
Analyst Consensus 1.5
Insider Activity NA
Price Volatility 3.0
Technical Moving Averages 0.0
Technical Oscillators 0.0
Average 1.13

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
DTIL 98 M - - 1.03
ELYM 553 M - - 1.55
CGEM 458 M - - 0.870
OMER 397 M - - 8.44
ZVRA 395 M - - 9.93
BNTC 383 M - - 4.63

Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.

Sector Healthcare
Industry Biotechnology
Investment Style Small Value
% Held by Insiders 9.40%
% Held by Institutions 46.49%

Ownership

Name Date Shares Held
Lynx1 Capital Management Lp 31 Dec 2024 766,051
Aquilo Capital Management, Llc 31 Dec 2024 536,376
52 Weeks Range
0.682 (-20%) — 2.21 (156%)
Median 60.00 (6,856.52%)
Total 1 Buy
Firm Date Target Price Call Price @ Call
HC Wainwright & Co. 28 Mar 2025 60.00 (6,856.52%) Buy 4.70
19 Mar 2025 60.00 (6,856.52%) Buy 5.01

No data within this time range.

Date Type Details
08 May 2025 Announcement Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025
07 May 2025 Announcement Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)
01 May 2025 Announcement Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
29 Apr 2025 Announcement Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
15 Apr 2025 Announcement Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B
01 Apr 2025 Announcement Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference
26 Mar 2025 Announcement Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update
21 Mar 2025 Announcement iECURE Announces Presentation of Full Data for the First Infant Dosed with ECUR-506 in OTC-HOPE Phase 1/2 Clinical Trial at the 2025 ACMG Annual Clinical Genetics Meeting
21 Mar 2025 Announcement Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025
20 Mar 2025 Announcement Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025
19 Mar 2025 Announcement Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
17 Mar 2025 Announcement Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B
24 Feb 2025 Announcement Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
19 Feb 2025 Announcement Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria